Company / Profit Margin
Haemonetics Profit Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
12.3%
FY2024
5-year range
4.4% / 12.3%
FY2020-FY2024
Trend
+37.2%
vs FY2023
Sector context
#29 of 150
Health Care
What the data says
Haemonetics's profit margin of 12.3% is higher than 81% of companies in the Health Care sector (FY2024). Profit Margin has fluctuated over the past 6 years, ranging from -3.0% in FY2016 to 20.2% in FY2017.
Based on SEC 10-K filings.
12.3% in FY2024 with a 3-year CAGR of +8.0%. Top quartile in the Health Care sector.
Improved from 9.9% to 12.3% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +8.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 19% in Health CareTop 19% of 150This company 12.3% Sector average -263.0%
▼
+104.7% above sector average
Key checks
Key Insights
- In FY2024, profit margin increased 37.2% year-over-year.
- Currently 275.3pp above the Health Care sector average.
- Peak profit margin was recorded in FY2017.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 12.3% | +37.2% |
| FY2023 | 9.0% | -9.0% |
| FY2022 | 9.9% | +125.9% |
| FY2021 | 4.4% | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | 20.2% | +783.1% |
| FY2016 | -3.0% | +51.6% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026